Thursday, October 29, 2020
4:00 PM PDT | 5:00 PM MDT| 6:00 PM CDT| 7:00 PM EDT
CLICK HERE TO REGISTER
NOTE: You will be asked to "sign in" or "sign up" to register for the program and then complete a brief pretest. Once you submit your answers, choose "next item". Upon registration, a link to access the webinar will be sent in a confirmation email.
Please contact firstname.lastname@example.org with any questions. Thank you!
Patricia A. Modica, OD, FAAO (Chair and Co-Presenter)
Assistant Clinical Professor
University Eye Center
State University of New York College of Optometry
New York, New York
Jeffrey L. Bennett, MD, PhD (Co-Presenter)
Gertrude Gilden Professor of Neurology and Ophthalmology
Department of Neurology
University of Colorado School of Medicine
CONTINUING EDUCATION INFORMATION
This activity intends to educate optometrists.
After completing this activity, participants will be better able to:
- Describe the pathophysiology of NMOSD
- Differentiate the clinical features of NMOSD from those of other demyelinating disorders
- Discuss best practices for referral of patients with suspected NMOSD
- Review clinical trial data for current treatments for NMOSD
COPE approved for 1.25 CE credits for optometrists.
COPE Course ID: 69946-NO (Interactive Distance Learning Course)
COPE Course Category: Neuro-Optometry
Instructions for Obtaining Credit
To obtain CE credit for this activity, participate in the webinar, consult referenced sources as necessary, and complete the posttest and evaluation online. After completing the posttest and evaluation, a certificate will be made available immediately.
MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any commercial interest. Financial relationship information is collected and resolved prior to the educational activity.
Jeffrey L. Bennett, MD, PhD, is a consultant for AbbVie Inc, Alexion Pharmaceuticals, Inc, Clene Nanomedicine, F. Hoffmann-La Roche Ltd,Genentech, Inc, Mitsubishi Tanabe Pharma America, Novartis Pharmaceuticals Corporation, Reistone Biopharma, and Viela Bio; is an advisory board member of F. Hoffmann-La Roche Ltd, Genentech, Inc, and TG Therapeutics, Inc; and is a contracted researcher for Novartis Pharmaceuticals Corporation.
Patricia A. Modica, OD, has no relevant commercial relationships to disclose.
Planners and Managers
MedEdicus planners and managers have no relevant commercial relationships to disclose.
Disclosure of Commercial Support
This continuing education activity is supported through an unrestricted educational grant from Genentech, Inc.
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at email@example.com.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the State University of New York College of Optometry, MedEdicus LLC, or Genentech, Inc.
This CE activity is copyrighted to MedEdicus LLC ©2020. All rights reserved. 224